한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

from the glow phase iii clinical trial to the research and development project targeting cldn18.2, researchers are trying to find drugs that can effectively treat patients through continuous exploration. these studies are aimed at evaluating the efficacy and safety of different therapies and bringing new hope to patients.

the glow phase iii clinical trial is a global, multicenter, double-blind, randomized phase iii trial. it uses a combination of zolpidem and mfolfox6 as a comparison group, and a placebo combined with mfolfox6 to evaluate its effect on patients' progression-free survival. the significance of this trial is that it can provide a more reliable treatment plan for clinical practice.

in addition to the glow phase iii clinical trial, another important research project is the development of new drugs for cldn18.2-positive metastatic pancreatic cancer. these drugs target the cldn18.2 protein in a unique way, looking for candidates that may become new therapeutic drugs.

during the research, scientists also worked to develop asp2138, a bispecific monoclonal antibody that binds to both cd3 and claudin 18.2. the drug is also being tested in a phase 1/1b clinical trial in patients with gastric cancer, gastroesophageal junction adenocarcinoma, or pancreatic cancer.

these research projects provide new directions for the treatment of cldn18.2-positive gastric cancer and demonstrate the researchers' pursuit and efforts for the future health of patients.